Bioanalysis Zone is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • Home
  • Awards
  • Events
  • Features
    • An author's perspective
    • Ask the Experts
    • Conference reports
    • eBooks
    • Expert opinion
    • In the Zone
    • Journal articles
    • Journal content
    • Spotlights
    • Tech Digest

    Follow us on social media

  • Glossary
  • Topics
    • Applications
      • Advanced therapies
      • Biomarkers
      • Clinical
      • Diagnostics
      • Drug development
      • Forensics
      • Patient-centric sampling
      • Sports drug testing
      • Toxicology
      • Vaccines
    • Industry updates & regulations
      • Biopharmaceuticals
      • Collaborations & mergers
      • Data processing and interpretation
      • Regulated bioanalysis
    • Molecules
      • Antibodies | ADCs
      • Biosimilars
      • Large molecules
      • Metabolites
      • Oligonucleotides
      • Small molecules
    • Techniques
      • Automation
      • Chromatography
      • Imaging
      • LBA
      • Microsampling
      • MS (LC–MS/MS, HRMS, IMS)
      • Sample preparation

    Follow us on social media

  • Multimedia
    • Coffee chats
    • Infographics
    • Interviews
    • Panel discussions
    • Podcasts
    • Videos
    • Webinars

    Follow us on social media

  • News
  • Partners
  • Register
[WEBINAR] Molecular bioanalysis considerations along the drug development journey 11 days 20 hours 5 mins 6 secs REGISTER NOW!

Why flow cytometry at KCAS? Solving the mysteries of flow cytometry

2 Jul 2018
General interest

KCAS has invested time and resources to qualify a number of multi-parameter immunophenotyping panels which can be utilized ‘off the shelf’ or customized to meet our client’s particular needs.

LB_Q3-spotlight-view

Top content

  • Waters launches the Xevo TQ Absolute XR at ASMS 2025
  • How can diagnostic laboratories accelerate the clinical adoption of allogeneic cell therapies?
  • Why NGS ELN deployments fail

Related tags

biomarker validation KCAS
Previous article Next article

Related articles

17 APR 2019 CLINICAL

Flow cytometry: tailored solutions without additional qualification

2 JUL 2018 GENERAL INTEREST

Flow cytometric immunophenotyping of PBMCs and quantification of cytokine production from patients in a peptide vaccine study

27 SEP 2018 GENERAL INTEREST

Immunogenicity assay development

28 JUN 2018 BIOMARKERS

Evolution of fit-for-purpose biomarker validations: an LBA perspective

25 JUL 2023 INTERVIEWS

Highlights from the 2023 WRIB conference and a look to the future for biomarkers from Jian Wang

2 JUL 2018 GENERAL INTEREST

Waters targeted omics library

  • About
  • Advertising & Sponsorship
  • Learn
    • Awareness
    • Education zone
    • Professional development
  • Contact Us
  • Permissions
  • Products
  • Zone Leaders
  • Whitelist Emails
Contact
Contact Us
Office info

Bioanalysis Zone is powered by Taylor & Francis Group

Bioanalysis Zone, 2-4 Park Square, Milton Park, Abingdon, Oxfordshire, OX14 4RN, United Kingdom
  • Taylor & Francis Group
  • Cookie Policy
  • Privacy Policy
  • Terms & Conditions
  • © 2025 Bioanalysis Zone